Skip to main content
Premium Trial:

Request an Annual Quote

Syrrx Completes $54 Million in Private Financing

NEW YORK, Jan 8 – Structural genomics company Syrrx expects to close a $54 million Series C round of venture funding Tuesday, the company announced Monday.

This financing effort follows an October 3 announcement that Syrrx had raised $20 million in Series B venture funding. The San Diego-based company has raised $79 million to date

Lombard Odier & Cie led this private placement, which included Bay City Capital, Chemicals and Materials Enterprise Associates (CMEA), CIBC, Cooper Hill, Invesco Global Health Science Fund, Jaspers, Joe Lewis, MPM Asset Management, Versant Ventures, Wanger Asset Management and Alex Zaffaroni.

Syrrx has developed an automated “factory approach” to determine structures of proteins, in collaboration with the Genomics Institute. The company uses this technology to enhance drug discovery efforts.

" This round of financing will enable Syrrx to deepen its commitment to industrializing protein structure determination with breakthrough technologies and add important competencies that will enable us to forward integrate to become a drug discovery company," Syrrx CEO Wendell Wierenga said in a statement.

Syrrx, which has 50 employees, recently began construction of an 84,000-square-foot facility, which it will occupy in January 2002.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.